- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 471/20 - Spiro-condensed systems
Patent holdings for IPC class C07D 471/20
Total number of patents in this class: 453
10-year publication summary
24
|
24
|
26
|
23
|
17
|
24
|
20
|
31
|
39
|
23
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Merck Sharp & Dohme LLC | 3756 |
38 |
Novartis AG | 10709 |
13 |
Boehringer Ingelheim International GmbH | 4648 |
12 |
Merck Patent GmbH | 5773 |
10 |
Pfizer Inc. | 3391 |
9 |
eFFECTOR Therapeutics, Inc. | 69 |
9 |
Shionogi & Co., Ltd. | 843 |
9 |
Vertex Pharmaceuticals Incorporated | 1626 |
8 |
Bristol-myers Squibb Company | 4850 |
7 |
The Regents of the University of Michigan | 4753 |
7 |
Incyte Corporation | 1028 |
7 |
Purdue Pharma L.P. | 502 |
7 |
Merck Sharp & Dohme Corp. | 2190 |
6 |
The Board of Trustees of the University of Illinois | 2711 |
6 |
Incyte Holdings Corporation | 668 |
6 |
SPV Therapeutics Inc. | 10 |
6 |
Glaxosmithkline Intellectual Property Development Limited | 767 |
5 |
The Broad Institute, Inc. | 1848 |
5 |
Oncopia Therapeutics, Inc. | 33 |
5 |
BeOne Medicines I GmbH | 107 |
5 |
Other owners | 273 |